



ICT-2011-8 Collaborative Project (Large-scale integrating project)

FAMOS

Functional anatomical molecular optical screening

Contract Number 317744
Project start date: 1 October 2012

Deliverable D10.2

Deliverable "Supply of Dissemination & Use Plan"

Organisation name Michelson Diagnostics Ltd

(lead contractor for deliverable)

Deliverable due date: M6

Date for submission: M6

Document revision: A (increment version if revising)

Dissemination level (select one)		
PU	Public	
PP	Restricted to other programme participants (including the Commission Services)	
RE	Restricted to a group specified by the consortium (including the Commission Services)	
СО	Confidential, only for members of the consortium (including the Commission Services)	Х





Author information

Author name: Jon Holmes

Organisation: (name & short name) Michelson Diagnostics Ltd - MDL

jon.holmes@vivosight.com +44 (0)208 308 1695 E-mail: Tel.

Additional document information

See 'Dissemination & Use Plan D10.2'

Project acronym: FAMOS Contract no.: 317744

Filename: FAMOS deliverable report D10.2.docx



Deliverable Report

Executive Summary

This document comprises the *plan* for managing the use & dissemination of foreground IP generated in FAMOS, during the project. It is expected that by the end of the project, further activities will be under way to exploit IP after the project ends, and this plan sets out how this goal will be achieved.

The PUDF is a contractual document that sets out in detail and verifiable manner the intentions and plans of the consortium partners to use and disseminate foreground IP. It is an evolving document that is updated during the project and is formally reviewed at **6-monthly intervals** and issued at **12 monthly intervals**.

The PUDF comprises two main sections, (1) Dissemination of Knowledge and (2) Exploitation, and a final section concerning Risks.

The Dissemination section deals with foreground IP that is put into the public domain. All of the content is by definition public. It addresses what publishable results have been produced, how they have been protected, and the method and location of dissemination, as well as which consortium members own it.

The Exploitation section deals with the plans for commercially exploiting Foreground IP. The content will be kept confidential (although of course disclosed to the European Commission).

It includes:

- The IP register all patent applications, trademarks, registered designs etc.
- Register of exploitable foreground, the anticipated resulting product, application, timetable for exploitation, the IP owner(s) and any 3rd parties involved in the exploitation.
- Detailed characterisation of each exploitation opportunity (market size assessment, competitive environment, regulatory & reimbursement barriers etc.)
- Details of any background IP required to exploit

The final section on Risks includes a register of any Risks that have been identified during the project:

- Technology risks eg. successful exploitation depends on development of new technology by partners outside the consortium
- Legal risks, eg potential to infringe 3rd parties' IPR
- Partnership risks, eg. Potential for conflicts of interest within the consortium if two parties wish to exploit the same IP, or disputes over IP ownership

Environmental, health or safety risks – any potential risks identified that could be created by the proposed new products